Table 1.

Pancreatic Cancer Clinical Trials of Nanomedicine Strategies for Drug Delivery (Referring from https://clinicaltrials.gov/)

Agent and Nanotechnology Approach	Status and Relevant Findings
NASOX: liposomal irinotecan with S-1 and oxaliplatin	Phase I/IIa
PanDox: thermoliposome doxorubicin	Phase I
Liposomal irinotecan with vactosertib, 5-FU and LV	Phase I
AGuIX gadolinium-chelated polysiloxane based nanoparticles with radiotherapy	Phase I/II
NBTXR3: hafnium oxide-containing nanoparticles with radiotherapy	Phase I
Nanoparticle paclitaxel albumin-bound protein in combination with ascorbic acid, cisplatin and gemcitabine	Phase I/II
Nanoparticle paclitaxel albumin-bound protein in combination with 5-FU, gemcitabine, cisplatin, irinotecan and folinic acid and radiotherapy	Phase II